PARTHENOLIDE: SUGGESTED DRUG FOR COVID-19

被引:0
|
作者
Nemati, M. [1 ]
Pouya, F. Danesh [1 ]
Asl, E. Roshni [1 ]
Rasmi, Y. [1 ,2 ]
机构
[1] Urmia Univ Med Sci, Dept Biochem, Sch Med, Orumiyeh, Iran
[2] Urmia Univ Med Sci, Cellular & Mol Res Ctr, Orumiyeh, Iran
来源
INFEKTSIYA I IMMUNITET | 2020年 / 10卷 / 04期
关键词
Parthenolide; COVID-19; NF-kappa B; ACTIVATION; INHIBITORS;
D O I
10.15789/2220-7619-PSD-1509
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the 2019 novel coronavirus (2019-nCoV) that causes acute respiratory distress syndrome (ARDS) which is the main reason for patients mortality. One of the effective treatments to reduce the effects of this virus is parthenolide (PN). Parthenolide is a sesquiterpene lactone found in medicinal plants. It can inhibit several pro-inflammatory signaling pathways, in particular the ATPase activity of NLRP3. Based on its ability to suppress inflammatory signal transduction and elevated level of serum IL-1 beta (a surrogate marker for NLRP3 activation) in COVID-19 patients, we suggest that PN could be potentiallyeffective for the treatment of COVID-19.
引用
收藏
页码:789 / 791
页数:3
相关论文
共 50 条
  • [41] Combating devastating COVID-19 by drug repurposing
    Pawar, Ashish Yashwantrao
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (02)
  • [42] COVID-19: Analysis of Drug Repositioning Practice
    P. I. Savosina
    D. S. Druzhilovskii
    V. V. Poroikov
    Pharmaceutical Chemistry Journal, 2021, 54 : 989 - 996
  • [43] Operating Facilities:- Suggested Guidelines to Cope COVID-19 in Third World Countries
    Saleem, Muhammad
    Ather, Uzma
    Saleem, Azka
    Saleem, Umer
    Iqbal, Asif
    Hashim, Imran
    Mirza, Muhammad Bilal
    Talat, Nabila
    Iqbal, Muhammad Javaid
    ANNALS OF KING EDWARD MEDICAL UNIVERSITY LAHORE PAKISTAN, 2020, 26 : 115 - 119
  • [44] Teicoplanin: an alternative drug for the treatment of COVID-19?
    Baron, Sophie Alexandra
    Devaux, Christian
    Colson, Philippe
    Raoult, Didier
    Rolain, Jean-Marc
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (04)
  • [45] Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?
    Devaux, Christian A.
    Melenotte, Clea
    Piercecchi-Marti, Marie-Dominique
    Delteil, Clemence
    Raoult, Didier
    FRONTIERS IN MEDICINE, 2021, 8
  • [46] A Review on Novel Drug Targets and Future Directions for COVID-19 Treatment
    Wondmkun, Yohannes Tsegyie
    Mohammed, Ousman Ahmed
    BIOLOGICS-TARGETS & THERAPY, 2020, 14 : 77 - 82
  • [47] Artificial Intelligence Technologies for COVID-19 De Novo Drug Design
    Floresta, Giuseppe
    Zagni, Chiara
    Gentile, Davide
    Patamia, Vincenzo
    Rescifina, Antonio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (06)
  • [48] Human cell receptors: potential drug targets to combat COVID-19
    Raghav, Pawan Kumar
    Kalyanaraman, Keerthana
    Kumar, Dinesh
    AMINO ACIDS, 2021, 53 (06) : 813 - 842
  • [49] Drug repurposing against coronavirus disease 2019 (COVID-19): A review
    Luo, Lianxiang
    Qiu, Qin
    Huang, Fangfang
    Liu, Kaifeng
    Lan, Yongqi
    Li, Xiaoling
    Huang, Yuge
    Cui, Liao
    Luo, Hui
    JOURNAL OF PHARMACEUTICAL ANALYSIS, 2021, 11 (06) : 683 - 690
  • [50] Sitagliptin: a potential drug for the treatment of COVID-19?
    Bardaweel, Sanaa K.
    Hajjo, Rima
    Sabbah, Dima A.
    ACTA PHARMACEUTICA, 2021, 71 (02) : 175 - 184